mix signal trajectori
post good howev optic softer spot us
devic slow despit libr confirm launch
though weak like tough comp chang trend
ou devic pick slack also saw good result
nutrit diagnost guidanc maintain could
feed question sustain growth dont see much alter
put take good sale result sale global
in-lin guidanc ep upper end
guidanc quarter saw number posit develop nutrit improv
includ good perform recent challeng intern pediatr
segment diagnost includ better expect initi contribut
aler busi devic overal still softer spot
us medic devic deceler despit libr
confirm rx launch overal result buoy intern sale us
libr trend note posit us diabet growth still
model us result rhythm manag vascular
structur heart well result result blame tougher
comp though also feed question whether run ahead challeng
commodit segment med-tech notabl area soft
epd doubl digit last year transient weak russia mexico
blame
guidanc maintain new product still key abbott remain firm
belief sustain recent trend guidanc maintain top-line
ep still question sustain recent strong result
like persist given weak sever larg segment us vascular epd
whether abbott off-set commodit read price challeng natur
continu page
price target ep upper-end large-
cap med-tech peer risk includ integr stj alr deal chines nutrit
market manufactur issu product recal
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
guidanc fine tune model guidanc includ doubl digit growth
establish pharma distribut channel outlet stabil key region
russia mexico low mid-singl digit nutrit support intern
market growth diagnost includ around sale contribut
rapid diagnost aler signific contribut alin full
menu offer sever region mid-to-upp singl digit medic devic
partial continu success libr launch confirm share captur well launch
xienc sierra go gross margin guid around
invest sg support name alin launch market
expans edp area focu nutrit ep guid rang
per share settl per share full year guidanc wasnt
chang model reflect slightli higher share count full year ep
price target goe ep
capit alloc prioriti remain debt servic share sharehold
return dividend prioriti action taken tone capit
alloc suggest intend stick prioriti laid last
primari use aggress debt paydown follow sharehold return gross
debt peak follow stj alr deal around
paid last year ahead expect gener remain robust
compani target anoth increment paydown
bring net debt ratio sharehold return come form
dividend buyback compani reiter pay-out ratio target
earn suggest aggreg payout year
 current math suggest dividend could expand
yield current share price tone slightli
shift ceo mile white mention top prioriti
remain opportunisticthough seem remain distant third prioriti cash
diabet solid libr gain initi us print littl light overal diabet
grew touch higher last continu global uptak
libr howev us perform light expect actual
addit commentari around libr bullish suggest strong adopt
market global activ user increas announc
user ad us thu far healthi mix new cgm user competit
captur balanc user mix two-third one-third expand global
reimburs two-third intern sale coverag despit
momentum particularli new patient volum still trend around per month
global us print modestli last year
sequenti regardless mix initi read like reflect
mismodel core bgm segment compani remain bullish libr us
launch prospect abbott forecast full-year come toward
higher-end previous issu target rang year
page
pleas see import disclosur inform page report
page
pleas see import disclosur inform page report
statementfy dec million except earn per report organ expens foreign exchang gain incom expens tax
page
pleas see import disclosur inform page report
